Current best practices and rationalistic perspectives in causation-based prevention, early detection and multidisciplinary treatment of breast and gastric cancer

Gastric & Breast Cancer e-journal
DOI: 10.2122/gbc.2010.0147

PERSPECTIVE

Eribulin, epigenome and miRNAs cancer therapeutics targets - Beyond?

Dimitrios H. Roukos, MD, PhD.

Affiliation: Personalized Cancer-Networks Medicine, Biobank, Ioannina University School of Medicine, Ioannina, 45110 Greece.

T: +302651007423, F: +302651007094

E-mail: droukos@uoi.gr

ABSTRACT

Recently, eribulin ľa nontaxane deep-sea sponge complex synthetic agent - was approved by the FDA. A phase III study (EMBRACE) has demonstrated an overall survival benefit (OS) of eribulin in heavily pre-treated patients with metastatic breast cancer. The eribulin FDA approval is more than just a triumph for patients in desperate need of treatment and represents a hard-won victory for the total synthesis of natural products.

Here I discuss the perspectives of eribulin in the adjuvant setting and the challenges to discover robust biomarkers for predicting resistance to taxane and eribulin sensitivity essential for decision making. Moreover, I describe new technologies-based latest advances with identification of epigenome modifications and microRNAs as therapeutic cancer targets that already are tested in clinical trails. In a more future perspective, I discuss how and why the future lies in the next-generation, biosystems interactions-based drugs considering emerging advances in cancer structural variation, genetic deregulation and cancer networks.

(Citation: Gastric & Breast Cancer 2011; 10(1): 1-18)

This article is 18 pages long, and includes 3 figures 2 tables and 1 box.

 

You can have an online full-text access and a PDF of this article:
  • Either purchase this paper for €50 EUR. Please, click here
Please specify DOI of article
  • Or through one year subscription PayPal

Online ISSN : 1109 - 7647
Print ISSN : 1109 - 7655

We subscribe to the HONcode principles of the HON Foundation. Click to verify. We subscribe to the HONcode principles. Verify here.
please, read our policy about privacy and confidentiality of information and transparency of sponsorship

last update: 8 February 2011